Monopar Therapeutics (MNPR) Treasury Shares (2020 - 2025)
Monopar Therapeutics' (MNPR) quarterly Treasury Shares came in at $550229.0 in Q4 2025, up 1250.62% year-on-year from $40739.0 in Q4 2024, and up 380.09% quarter-over-quarter from $114610.0 in Q3 2025.
Monopar Therapeutics (MNPR) Treasury Shares (2020 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Treasury Shares across 6 years of filings, most recently posting $550229.0 for Q4 2025.
- Treasury Shares for Q4 2025 came in at $550229.0, up 1250.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $550229.0 (up 1250.62% YoY), and the FY2025 annual result was $550229.0, up 1250.62% from the prior year.
- Treasury Shares came in at $550229.0 for Q4 2025 at Monopar Therapeutics, up from $114610.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $550229.0 in Q4 2025 to a low of $40739.0 in Q4 2024.
- The 5-year median for Treasury Shares is $149364.0 (2025), against an average of $238567.7.
- Across the five-year window, Treasury Shares sank 89.86% in 2024 and jumped 1250.62% in 2025, its largest moves.
- Monopar Therapeutics' Treasury Shares stood at $111462.0 in 2021, then slumped by 51.08% to $54529.0 in 2022, then jumped by 53.34% to $83617.0 in 2023, then sank by 51.28% to $40739.0 in 2024, then surged by 1250.62% to $550229.0 in 2025.
- The last three Treasury Shares figures came in at $550229.0 (Q4 2025), $114610.0 (Q3 2025), and $128408.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | 550,229.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 550,229.00 |
| Dec 31, 2025 | 550,229.00 |
| Sep 30, 2025 | 114,610.00 |
| Sep 30, 2025 | 114,610.00 |
| Jun 30, 2025 | 128,408.00 |
| Jun 30, 2025 | 128,408.00 |
| Mar 31, 2025 | 149,364.00 |
| Mar 31, 2025 | 149,364.00 |
| Dec 31, 2024 | 40,739.00 |
| Dec 31, 2024 | 40,739.00 |
| Sep 30, 2024 | 47,843.00 |
| Sep 30, 2024 | 47,843.00 |
| Jun 30, 2024 | 349,154.00 |
| Jun 30, 2024 | 349,154.00 |
| Mar 31, 2024 | 366,534.00 |
| Mar 31, 2024 | 366,534.00 |
| Dec 31, 2023 | 83,617.00 |
| Dec 31, 2023 | 83,617.00 |
| Sep 30, 2023 | 471,828.00 |
| Sep 30, 2023 | 471,828.00 |